In a fraction of SARS-CoV-2 infected individuals treated with the oral antiviral Paxlovid, the virus rebounds following treatment. The mechanism driving rebound is not understood. Here, we show that viral dynamic models based on the hypothesis that Paxlovid treatment near the time of symptom onset halts the depletion of target cells, but may not fully eliminate the virus, which can lead to viral…
Not reinstating the funding “would be a moral stain on this Administration and Congress’s legacy,” the groups said in a joint letter, which was first…
The HIV research community is led by scientists with deep personal commitments to improving the lives of people with and affected by HIV. Our collective…
This is a summary of what was said by UNICEF Communication Specialist Tess Ingram – to whom quoted text may be attributed – at today’s…
The most significant case in decades on homelessness has reached the Supreme Court as record numbers of people in America are without a permanent place…
This Viewpoint discusses the importance of the US Congress reauthorizing funding for the President’s Emergency Plan for AIDS Relief, a program developed in 2003 that…
U.S. National Institutes of Health guidelines currently recommend nirmatrelvir/ritonavir (Paxlovid) as first-line therapy for outpatients with COVID-19
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. NIAID supports research across the spectrum from basic to clinical science to develop effective…
Background: Long-acting antiretroviral therapy (LA-ART) is novel and has been used for both virologically-suppressed (VS) and viremic patients with adherence challenges. The currently-approved LA-ART combination…
Samantha Power becomes first US official to confirm famine, while aid workers decry continuing lack of help
Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an…
